The FDA granted accelerated approval to Dizal Pharmaceutical’s sunvozertinib (Zegfrovy) for adults with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations after platinum chemotherapy. As a targeted oral therapy with priority review and breakthrough designation, sunvozertinib offers a new option for this subset of lung cancer patients. Companion diagnostic approval for Thermo Fisher's Oncomine Dx Express Test further facilitates patient identification. Dizal aims to compete with J&J’s Rybrevant, highlighting safety and efficacy improvements. Confirmatory trials continue to verify long-term benefits.